314-726-6700 | Email
Karen Gheesling Mullis, Ph.D., PMP, serves as president of RiverVest’s Archer Seed Partners, LLC, investing in early-stage biopharmaceutical companies primarily in St. Louis and elsewhere in the Midwest.
Karen is tasked with sourcing and conducting due diligence on investment opportunities for the Archer Seed Fund and then overseeing the development activities of the companies in which the fund invests.
Prior to joining RiverVest in 2016, Karen served as director of project management at Pfizer (previously Pharmacia/Monsanto/Searle), where she led the clinical development and registration of several breakthrough cancer therapy drugs including Ibrance and Xalkori Ros1.
“Our Archer Seed Fund will not only benefit from St. Louis’ assets, it will also accelerate and contribute to our startup ecosystem.”
Karen received her Ph.D. in Biochemistry from the University of Alabama, Birmingham, her B.S. in Chemistry from Emory University and was a Post-Doctoral Research Fellow in the Division of Hematology and Oncology at Washington University School of Medicine in St. Louis.